An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory P hiladelphia chromosome‐positive acute lymphoblastic leukemia

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

(2020) Robin Foà et al.   NEW ENGLAND JOURNAL OF MEDICINE

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

(2020) Courtney D DiNardo et al.   Lancet Haematology

Ibrutinib and Venetoclax for First-Line Treatment of CLL

(2019) Nitin Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

(2019) Kirsten Fischer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors

(2019) Iman Abou Dalle et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pathways and mechanisms of venetoclax resistance

(2017) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2016) N. J. Short et al.   BLOOD

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia

(2016) Jessica T. Leonard et al.   Science Translational Medicine

Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

(2013) Ohad Benjamini et al.   AMERICAN JOURNAL OF HEMATOLOGY

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

(2013) M Scherr et al.   LEUKEMIA

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE